At 03:22 AM 1/9/2005, you wrote:
>FROM:   Medical Letter on the CDC & FDA
>  January 9, 2005
>
>SECTION: EXPANDED REPORTING; Pg. 94
>
>HEADLINE: PARKINSON DISEASE;
>Biotech firm gets NIH grant to study environmental causes of Parkinson
>disease
>
>     RxGen, Inc., a private biotechnology company, announced that the
>National
>Institutes of Health (NIH) has funded phase 1 of the company's Fast Track
>SBIR
>grant for $1.1 million to uncover genomic markers of Parkinson disease.
>
>     RxGen is using genomics and bioinformatics technologies and knowledge
>of
>primate models of Parkinson disease to profile in vivo brain RNA
>expression
>patterns following exposure to compounds known to cause the neuronal
>injury and
>dopamine depletion associated with Parkinson disease.
>
>     RxGen's plans to profile toxins such as rotenone,

>tetrahydroisoquinolone,     Has anyone  studied thre effects of the usages
>OF   DDT
>ithiocarbamate, and Paraquat, which have been implicated as possible
>environmental causes of Parkinson disease. This grant will enable RxGen
>to
>examine critical pathways of injury and neuroprotection specific to
>dopaminergic
>neurons, which may set the stage for developing therapeutic
>interventions.
>
>     The NIH SBIR funding will help RxGen advance its internal research
>and
>development programs associated with predictive toxicology and central
>nervous
>system drug discovery. RxGen's predictive toxicology technology program,
>PrimaTox, was recently funded by the NIH through a separate Fast Track
>SBIR
>award of $1.4 million.
>
>     RxGen has access to a primate facility with 27 years of experience in
>research pertaining to Parkinson disease and other neurodegenerative
>conditions
>and related therapeutic strategies.
>
>     RxGen, Inc. is focused on the development of therapeutics for
>neurodegeneration, memory loss, obesity and other central nervous system
>disorders using animal models of human disease and leading genomics and
>bioinformatics.
>
>     This article was prepared by Medical Letter on the CDC  &  FDA
>editors from
>staff and other reports.  Copyright 2005, Medical Letter on the CDC  &
>FDA via
>NewsRx.com  &  NewsRx.net.
>
>----------------------------------------------------------------------
>To sign-off Parkinsn send a message to: mailto:[log in to unmask]
>In the body of the message put: signoff parkinsn

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn